๐ŸŒ MRCS Part A ยท subject

MRCS Part A Pharmacology Syllabus

The Pharmacology syllabus for MRCS Part A in full: 8 chapters, 30 topics and 97 sub-topics, every one listed below, plus 57 Pharmacology flashcards with answers.

8Chapters
30Topics
97Sub-topics
57Flashcards

Pharmacology syllabus: all 8 chapters

Expand any chapter to see its topics and sub-topics.

  1. General Pharmacology

    5 topics
    • Introduction to Pharmacology
      • Definition and Scope
      • Branches of Pharmacology
      • Sources of Drugs
    • Pharmacokinetics
      • Absorption
      • Distribution
      • Metabolism
      • Excretion
    • Pharmacodynamics
      • Mechanism of Drug Action
      • Dose-Response Relationship
      • Therapeutic Index
    • Drug Receptors
      • Types of Receptors
      • Receptor Theories
      • Receptor Regulation
    • Adverse Drug Reactions
      • Types of Adverse Reactions
      • Drug Toxicity
      • Management of Adverse Reactions
  2. Autonomic Nervous System Pharmacology

    2 topics
    • Cholinergic Drugs
      • Cholinergic Agonists
      • Cholinesterase Inhibitors
      • Anticholinergic Drugs
    • Adrenergic Drugs
      • Adrenergic Agonists
      • Adrenergic Antagonists
      • Indirect-Acting Adrenergic Agents
  3. Cardiovascular Pharmacology

    4 topics
    • Antihypertensive Drugs
      • Diuretics
      • Beta-Blockers
      • Calcium Channel Blockers
      • ACE Inhibitors
      • ARBs
    • Antianginal Drugs
      • Nitrates
      • Beta-Blockers
      • Calcium Channel Blockers
    • Antiarrhythmic Drugs
      • Classification of Antiarrhythmics
      • Mechanism of Action
      • Clinical Uses
    • Drugs for Heart Failure
      • Cardiac Glycosides
      • Diuretics
      • ACE Inhibitors
      • Beta-Blockers
  4. Central Nervous System Pharmacology

    5 topics
    • Anxiolytics and Hypnotics
      • Benzodiazepines
      • Barbiturates
      • Non-Benzodiazepine Hypnotics
    • Antidepressants
      • SSRIs
      • SNRIs
      • Tricyclic Antidepressants
      • MAO Inhibitors
    • Antipsychotics
      • Typical Antipsychotics
      • Atypical Antipsychotics
    • Antiepileptic Drugs
      • Mechanism of Action
      • Classification of Antiepileptics
      • Clinical Uses
    • Analgesics
      • Opioid Analgesics
      • Non-Opioid Analgesics
      • Adjuvant Analgesics
  5. Endocrine Pharmacology

    4 topics
    • Drugs for Diabetes Mellitus
      • Insulin
      • Oral Hypoglycemic Agents
      • Non-Insulin Injectable Agents
    • Thyroid and Antithyroid Drugs
      • Thyroid Hormones
      • Antithyroid Drugs
    • Corticosteroids
      • Glucocorticoids
      • Mineralocorticoids
      • Clinical Uses and Adverse Effects
    • Sex Hormones
      • Estrogens
      • Progestins
      • Androgens
  6. Chemotherapy

    4 topics
    • Antibacterial Drugs
      • Penicillins
      • Cephalosporins
      • Macrolides
      • Quinolones
      • Aminoglycosides
    • Antiviral Drugs
      • Antiretrovirals
      • Antiviral Agents for Herpesviruses
      • Antiviral Agents for Influenza
    • Antifungal Drugs
      • Azoles
      • Echinocandins
      • Polyenes
    • Anticancer Drugs
      • Alkylating Agents
      • Antimetabolites
      • Natural Products
      • Targeted Therapies
  7. Respiratory Pharmacology

    3 topics
    • Drugs for Asthma
      • Beta-Agonists
      • Corticosteroids
      • Leukotriene Modifiers
    • Drugs for COPD
      • Bronchodilators
      • Phosphodiesterase-4 Inhibitors
      • Combination Therapies
    • Antitussives and Expectorants
      • Opioid Antitussives
      • Non-Opioid Antitussives
      • Expectorants
  8. Gastrointestinal Pharmacology

    3 topics
    • Drugs for Peptic Ulcer Disease
      • Proton Pump Inhibitors
      • H2 Receptor Antagonists
      • Antacids
    • Antiemetic Drugs
      • Serotonin Antagonists
      • Dopamine Antagonists
      • Antihistamines
    • Laxatives and Antidiarrheal Drugs
      • Bulk-Forming Laxatives
      • Stimulant Laxatives
      • Osmotic Laxatives
      • Antidiarrheal Agents

MRCS Part A Pharmacology flashcards โ€” 57 questions with answers

  1. Define pharmacology, and distinguish its two main branches, pharmacokinetics and pharmacodynamics.

    Pharmacology is the study of the interaction of drugs with living systems. Pharmacokinetics is what the body does to the drug (absorption, distribution, metabolism, excretion), whereas pharmacodynamics is what the drug does to the body (mechanism of action and effects).

  2. What is the difference between a drug's therapeutic index and its therapeutic window?

    The therapeutic index is a ratio comparing the dose that produces toxicity to the dose that produces the desired effect, $TI = \frac{TD_{50}}{ED_{50}}$ (or $\frac{LD_{50}}{ED_{50}}$). The therapeutic window is the range of plasma concentrations between the minimum effective concentration and the minimum toxic concentration. A high TI/wide window means a safer drug.

  3. What are the four processes described by the acronym ADME in pharmacokinetics?

    Absorption, Distribution, Metabolism, and Excretion.

  4. Define bioavailability (F) and give the formula for oral bioavailability.

    Bioavailability is the fraction of an administered dose reaching the systemic circulation unchanged. $F = \frac{AUC_{oral}}{AUC_{IV}} \times \frac{Dose_{IV}}{Dose_{oral}}$. Intravenous administration has $F = 1$ (100%).

  5. What is the volume of distribution ($V_d$) and how is it calculated?

    $V_d$ is the apparent volume needed to contain the total amount of drug at the same concentration as in plasma. $V_d = \frac{\text{Total amount of drug in body}}{\text{Plasma concentration}} = \frac{Dose}{C_0}$. A large $V_d$ indicates extensive tissue distribution.

  6. Distinguish zero-order from first-order elimination kinetics.

    In first-order kinetics a constant fraction of drug is eliminated per unit time (rate proportional to concentration), giving a constant half-life. In zero-order (saturation) kinetics a constant amount is eliminated per unit time regardless of concentration; e.g. ethanol, phenytoin, high-dose aspirin.

  7. Give the relationship between elimination half-life ($t_{1/2}$), volume of distribution ($V_d$) and clearance (CL).

    $$t_{1/2} = \frac{0.693 \times V_d}{CL}$$ where $0.693 = \ln 2$. Half-life is directly proportional to $V_d$ and inversely proportional to clearance.

  8. After how many half-lives is a drug considered essentially eliminated (or steady state reached on repeated dosing)?

    Approximately 4โ€“5 half-lives. After 4 half-lives ~94% is eliminated, after 5 half-lives ~97%. Steady state on constant dosing is likewise reached in ~4โ€“5 half-lives.

  9. What is the difference between Phase I and Phase II reactions in drug metabolism?

    Phase I reactions (oxidation, reduction, hydrolysis; mainly cytochrome P450) introduce or unmask a functional group, often producing a more polar or active metabolite. Phase II reactions are conjugations (glucuronidation, sulfation, acetylation, methylation, glutathione) that attach an endogenous molecule to increase water solubility for excretion.

  10. What is first-pass metabolism and how can it be avoided?

    First-pass metabolism is the metabolism of an orally absorbed drug by the gut wall and liver before it reaches the systemic circulation, reducing bioavailability. It can be bypassed by sublingual, rectal, transdermal, inhalational, or parenteral (IV/IM/SC) routes.

  11. State the loading dose and maintenance dose formulas.

    $$\text{Loading dose} = \frac{C_{target} \times V_d}{F}$$ $$\text{Maintenance dose rate} = \frac{C_{target} \times CL}{F}$$ where $F$ is bioavailability.

  12. Define pharmacodynamics terms: agonist, antagonist, and partial agonist.

    An agonist binds a receptor and produces a maximal response (full intrinsic activity). A partial agonist binds but produces only a submaximal response even at full occupancy (intrinsic activity between 0 and 1). An antagonist binds but produces no response (intrinsic activity 0) and blocks agonist action.

  13. Distinguish competitive from non-competitive (irreversible) antagonism in terms of effect on the agonist dose-response curve.

    A competitive antagonist shifts the agonist dose-response curve to the right in a parallel fashion (increased $EC_{50}$) but $E_{max}$ is unchanged and surmountable by more agonist. A non-competitive/irreversible antagonist reduces $E_{max}$ (non-surmountable) and cannot be overcome by increasing agonist.

  14. Define potency and efficacy, and state which parameters represent them.

    Potency is the amount of drug needed to produce a given effect, represented by $EC_{50}$ (lower $EC_{50}$ = more potent). Efficacy is the maximal effect a drug can produce, represented by $E_{max}$.

  15. What does $ED_{50}$ mean and how does it relate to $LD_{50}$?

    $ED_{50}$ is the dose producing the therapeutic effect in 50% of the population; $LD_{50}$ is the dose that is lethal in 50%. The ratio $\frac{LD_{50}}{ED_{50}}$ gives the therapeutic index.

  16. Name the four major types of drug (cell-surface/intracellular) receptors by signalling mechanism.

    1) Ligand-gated ion channels (ionotropic, e.g. nicotinic, GABA-A) โ€” milliseconds; 2) G-protein-coupled receptors (metabotropic, e.g. muscarinic, adrenergic) โ€” seconds; 3) Enzyme-linked/kinase-linked receptors (e.g. insulin, tyrosine kinase) โ€” minutes; 4) Intracellular/nuclear receptors (e.g. steroids, thyroid hormone) โ€” hours.

  17. What second messengers are generated by $G_s$, $G_i$, and $G_q$ protein-coupled receptors?

    $G_s$ activates adenylyl cyclase, increasing cAMP. $G_i$ inhibits adenylyl cyclase, decreasing cAMP. $G_q$ activates phospholipase C, producing IP3 (releases $\ce{Ca^2+}$) and DAG (activates protein kinase C).

  18. Define tachyphylaxis and distinguish it from tolerance.

    Tachyphylaxis is a rapid decrease in response after repeated doses over a short period (e.g. minutes to hours), often due to receptor desensitization or mediator depletion. Tolerance is a slower, progressive decrease in response requiring higher doses, developing over days to weeks.

  19. Classify adverse drug reactions using the Rawlins-Thompson Type A vs Type B system.

    Type A (Augmented) reactions are dose-dependent, predictable, related to the drug's pharmacology, common, and low mortality (e.g. bleeding with warfarin). Type B (Bizarre) reactions are dose-independent, unpredictable, not related to known pharmacology, rare, but higher mortality (e.g. anaphylaxis, idiosyncratic reactions).

  20. List the four Gell and Coombs types of hypersensitivity reactions with a drug example each.

    Type I โ€” IgE-mediated immediate/anaphylaxis (penicillin anaphylaxis); Type II โ€” antibody-mediated cytotoxic (methyldopa haemolytic anaemia); Type III โ€” immune-complex mediated (serum sickness); Type IV โ€” delayed T-cell mediated (contact dermatitis, Stevens-Johnson syndrome).

Show the other 37 Pharmacology flashcards
  1. Where is acetylcholine the neurotransmitter in the autonomic nervous system?

    Acetylcholine acts at: all preganglionic autonomic fibres (sympathetic and parasympathetic) at nicotinic ganglionic receptors; all postganglionic parasympathetic fibres at muscarinic receptors; postganglionic sympathetic fibres to sweat glands; the adrenal medulla; and the somatic neuromuscular junction (nicotinic).

  2. Contrast the effects of muscarinic agonists (parasympathetic) at the eye, heart, and secretions.

    Muscarinic stimulation causes: pupil constriction (miosis) and ciliary muscle contraction (accommodation, reduced intraocular pressure); decreased heart rate (negative chronotropy) and slowed AV conduction; and increased secretions (salivary, lacrimal, bronchial, GI) โ€” remembered as SLUDGE effects.

  3. What are the clinical features of organophosphate (irreversible anticholinesterase) poisoning and its antidotes?

    Cholinergic crisis: salivation, lacrimation, urination, defecation, GI cramps, emesis (SLUDGE), plus bronchospasm, bradycardia, miosis, muscle fasciculations and weakness. Treatment: atropine (blocks muscarinic effects) plus pralidoxime (regenerates acetylcholinesterase if given before ageing).

  4. Compare the actions of atropine, glycopyrrolate and hyoscine (scopolamine) as antimuscarinics.

    All are muscarinic antagonists. Atropine crosses the blood-brain barrier (central effects, tachycardia, mydriasis). Glycopyrrolate is quaternary and does not cross the BBB (no CNS effects; used to dry secretions and block vagal reflexes). Hyoscine crosses the BBB and is strongly antiemetic/sedative (motion sickness), with more central antimuscarinic action.

  5. Describe the synthesis pathway of noradrenaline (norepinephrine) and the rate-limiting step.

    $$\text{Tyrosine} \to \text{DOPA} \to \text{Dopamine} \to \text{Noradrenaline} \to \text{Adrenaline}$$ Tyrosine hydroxylase converts tyrosine to DOPA and is the rate-limiting enzyme. The final conversion of noradrenaline to adrenaline (by PNMT) occurs mainly in the adrenal medulla.

  6. Summarise the main effects of the adrenergic receptor subtypes $\alpha_1$, $\alpha_2$, $\beta_1$, $\beta_2$.

    $\alpha_1$: vasoconstriction, mydriasis, bladder sphincter contraction ($G_q$). $\alpha_2$: presynaptic inhibition of noradrenaline release, reduced central sympathetic outflow ($G_i$). $\beta_1$: increased heart rate, contractility and renin release ($G_s$). $\beta_2$: bronchodilation, vasodilation, uterine relaxation, glycogenolysis ($G_s$).

  7. How does the effect of adrenaline on blood pressure differ at low versus high doses (epinephrine reversal)?

    At low doses, $\beta_2$-mediated vasodilation predominates and can lower diastolic BP; at high doses $\alpha_1$-mediated vasoconstriction dominates, raising BP. If an $\alpha$-blocker is given, adrenaline's pressor effect is reversed to a depressor effect (epinephrine reversal) because unopposed $\beta_2$ vasodilation remains.

  8. List the major classes of antihypertensive drugs with one example each.

    Diuretics (thiazides, e.g. bendroflumethiazide); ACE inhibitors (ramipril); Angiotensin receptor blockers (losartan); Calcium channel blockers (amlodipine); Beta-blockers (bisoprolol); Alpha-blockers (doxazosin); Centrally acting (methyldopa, clonidine); Direct vasodilators (hydralazine).

  9. Explain the mechanism of ACE inhibitors and their most characteristic side effect.

    ACE inhibitors block angiotensin-converting enzyme, reducing conversion of angiotensin I to angiotensin II (less vasoconstriction and aldosterone) and reducing bradykinin breakdown. The characteristic side effect is a dry cough (from bradykinin accumulation); they can also cause hyperkalaemia, first-dose hypotension and angioedema, and are contraindicated in pregnancy and bilateral renal artery stenosis.

  10. Contrast dihydropyridine and non-dihydropyridine calcium channel blockers.

    Dihydropyridines (e.g. amlodipine, nifedipine) act mainly on vascular smooth muscle causing vasodilation, with reflex tachycardia possible. Non-dihydropyridines (verapamil, diltiazem) act more on the heart, reducing heart rate and contractility (negative chronotropy/inotropy) โ€” useful for rate control but should not be combined with beta-blockers.

  11. What is the first-line management order for essential hypertension using the ACD/step approach (e.g. NICE)?

    Under 55 or type 2 diabetic (any age, non-Black): start with an ACE inhibitor/ARB (A). Over 55 or Black African/Caribbean origin: start with a calcium channel blocker (C). Step 2: A + C. Step 3: A + C + thiazide-like diuretic (D). Step 4 (resistant): add spironolactone if $K^{+} \leq 4.5$, or alpha/beta-blocker.

  12. How does glyceryl trinitrate (GTN) relieve angina?

    GTN is metabolised to nitric oxide, which activates guanylyl cyclase to raise cGMP, causing vascular smooth muscle relaxation. Predominant venodilation reduces preload (and thus myocardial oxygen demand); it also dilates coronary arteries. Given sublingually to bypass extensive first-pass metabolism.

  13. Name the three main drug classes used for chronic stable angina and how each reduces myocardial oxygen demand.

    Nitrates โ€” venodilation reduces preload. Beta-blockers โ€” reduce heart rate and contractility (lower oxygen demand, prolong diastolic coronary filling). Calcium channel blockers โ€” reduce afterload (vasodilation) and, for non-dihydropyridines, heart rate/contractility. Others: ivabradine, nicorandil, ranolazine.

  14. Why must nitrates never be co-prescribed with phosphodiesterase-5 inhibitors such as sildenafil?

    PDE-5 inhibitors block breakdown of cGMP while nitrates increase cGMP; together they cause excessive vasodilation and profound, potentially fatal hypotension.

  15. State the Vaughan-Williams classification of antiarrhythmic drugs.

    Class I โ€” sodium channel blockers (Ia quinidine, Ib lidocaine, Ic flecainide); Class II โ€” beta-blockers; Class III โ€” potassium channel blockers/prolong repolarization (amiodarone, sotalol); Class IV โ€” non-dihydropyridine calcium channel blockers (verapamil, diltiazem). Unclassified: adenosine, digoxin, magnesium.

  16. List the key adverse effects of amiodarone.

    Pulmonary fibrosis, thyroid dysfunction (hypo- and hyperthyroidism, due to iodine content), hepatotoxicity, corneal microdeposits, blue-grey skin/photosensitivity, peripheral neuropathy, and QT prolongation. It has a very long half-life (weeks to months).

  17. How does adenosine terminate supraventricular tachycardia, and what is its half-life?

    Adenosine activates $A_1$ receptors, opening potassium channels and inhibiting calcium currents in the AV node, causing transient AV block that terminates re-entrant SVT. It has an extremely short half-life (<10 seconds) so is given as a rapid IV bolus; effects are antagonised by theophylline/caffeine and potentiated by dipyridamole.

  18. Explain the mechanism of action of digoxin and its therapeutic uses.

    Digoxin inhibits the $\ce{Na+/K+}$-ATPase, raising intracellular $\ce{Na+}$, which reduces $\ce{Na+/Ca^2+}$ exchange and increases intracellular $\ce{Ca^2+}$ โ€” giving positive inotropy. It also increases vagal tone, slowing AV conduction. Used for rate control in atrial fibrillation and in heart failure. Toxicity is worsened by hypokalaemia.

  19. Which drug classes reduce mortality in heart failure with reduced ejection fraction (HFrEF)?

    ACE inhibitors/ARBs (or ARNI, sacubitril-valsartan), beta-blockers (bisoprolol, carvedilol, nebivolol), mineralocorticoid receptor antagonists (spironolactone, eplerenone), and SGLT2 inhibitors (dapagliflozin, empagliflozin) โ€” the 'four pillars'. Diuretics relieve symptoms but do not reduce mortality.

  20. Compare benzodiazepines and barbiturates in their action on the GABA-A receptor.

    Both enhance GABA-A chloride channel activity. Benzodiazepines increase the frequency of channel opening (require GABA to act) and have a ceiling effect, making them safer. Barbiturates increase the duration of channel opening and at high doses open the channel directly (GABA-independent), giving no ceiling effect and greater lethality in overdose.

  21. What is the antidote for benzodiazepine overdose and how does it work?

    Flumazenil, a competitive antagonist at the benzodiazepine binding site of the GABA-A receptor. Used cautiously as it can precipitate seizures, especially in chronic users or mixed overdoses.

  22. By what mechanism do SSRIs treat depression, and name two of their notable adverse effects.

    SSRIs (e.g. fluoxetine, sertraline) selectively inhibit the presynaptic serotonin (5-HT) transporter, increasing synaptic serotonin. Notable adverse effects: GI upset and initial anxiety, sexual dysfunction, hyponatraemia (SIADH), increased bleeding risk, and serotonin syndrome (especially in combination with other serotonergic drugs).

  23. What dietary and drug interaction is dangerous with non-selective irreversible MAO inhibitors?

    Tyramine-rich foods (aged cheese, cured meats, red wine) can trigger a hypertensive crisis (the 'cheese reaction') because MAO normally metabolises tyramine. Combining MAOIs with other serotonergic drugs (SSRIs, opioids like pethidine) risks serotonin syndrome; a washout period is required when switching.

  24. Distinguish typical from atypical antipsychotics in mechanism and side-effect profile.

    Typical (first-generation, e.g. haloperidol, chlorpromazine) are potent $D_2$ receptor antagonists with high risk of extrapyramidal side effects and hyperprolactinaemia. Atypical (second-generation, e.g. olanzapine, risperidone, clozapine) block $D_2$ and $5\text{-}HT_2$ receptors, with fewer extrapyramidal effects but greater metabolic side effects (weight gain, diabetes, dyslipidaemia).

  25. What are the extrapyramidal side effects of antipsychotics and their typical time course?

    Acute dystonia (hours to days), akathisia (days to weeks), parkinsonism (weeks to months), and tardive dyskinesia (months to years, often irreversible). They result from $D_2$ blockade in the nigrostriatal pathway.

  26. What is neuroleptic malignant syndrome and how is it managed?

    A rare, life-threatening reaction to dopamine antagonists (antipsychotics) presenting with hyperthermia, 'lead-pipe' muscle rigidity, altered consciousness, autonomic instability, and raised creatine kinase. Management: stop the causative drug, supportive cooling and fluids, and dantrolene or bromocriptine.

  27. Match these antiepileptic drugs to their principal mechanisms: phenytoin/carbamazepine, valproate, ethosuximide, and benzodiazepines/barbiturates.

    Phenytoin and carbamazepine block voltage-gated sodium channels (prolong inactivation). Sodium valproate has multiple actions (Na channel block, increased GABA). Ethosuximide blocks T-type calcium channels (drug of choice for absence seizures). Benzodiazepines and barbiturates enhance GABA-A activity.

  28. Why is sodium valproate avoided in women of childbearing age?

    Valproate is highly teratogenic, causing neural tube defects (spina bifida), congenital malformations and neurodevelopmental impairment. It is also hepatotoxic and can cause pancreatitis, weight gain, tremor and hair loss.

  29. Explain the WHO analgesic ladder for pain management.

    Step 1: non-opioid ยฑ adjuvant (paracetamol, NSAIDs) for mild pain. Step 2: weak opioid (codeine, tramadol) ยฑ non-opioid ยฑ adjuvant for moderate pain. Step 3: strong opioid (morphine) ยฑ non-opioid ยฑ adjuvant for severe pain. Adjuvants include antidepressants and anticonvulsants for neuropathic pain.

  30. Describe the mechanism of action of NSAIDs and contrast COX-1 versus COX-2 inhibition.

    NSAIDs inhibit cyclo-oxygenase (COX), reducing prostaglandin synthesis (anti-inflammatory, analgesic, antipyretic). COX-1 is constitutive (protects gastric mucosa, supports platelet function and renal perfusion), so its inhibition causes GI ulceration and bleeding. COX-2 is induced at sites of inflammation; selective COX-2 inhibitors (celecoxib) spare the stomach but increase cardiovascular thrombotic risk.

  31. How do opioids produce analgesia and what are the features of opioid toxicity?

    Opioids agonise $\mu$ (and $\kappa$, $\delta$) receptors โ€” G-protein coupled โ€” reducing neurotransmitter release and hyperpolarising neurons, decreasing pain transmission. Toxicity: the triad of respiratory depression, pinpoint pupils (miosis) and reduced consciousness, plus constipation and hypotension. Antidote: naloxone (competitive $\mu$ antagonist).

  32. Classify insulin preparations by onset and duration of action.

    Rapid-acting (lispro, aspart): onset ~15 min, peak ~1 h, duration 3โ€“5 h. Short-acting (regular/soluble): onset ~30 min, duration 6โ€“8 h. Intermediate (NPH/isophane): onset 1โ€“2 h, duration 12โ€“18 h. Long-acting (glargine, detemir): onset 1โ€“2 h, flat profile, duration ~24 h.

  33. State the mechanism of action of metformin and its major serious adverse effect.

    Metformin is a biguanide that decreases hepatic gluconeogenesis, increases peripheral insulin sensitivity and glucose uptake, and reduces intestinal glucose absorption; it does not cause hypoglycaemia or weight gain. Its major serious adverse effect is lactic acidosis (especially in renal impairment); it should be withheld around contrast/surgery.

  34. Compare the mechanisms of sulfonylureas, DPP-4 inhibitors, GLP-1 agonists and SGLT2 inhibitors.

    Sulfonylureas (gliclazide) close $K_{ATP}$ channels on beta-cells to stimulate insulin release (risk hypoglycaemia, weight gain). DPP-4 inhibitors (sitagliptin) block incretin breakdown, raising GLP-1. GLP-1 agonists (semaglutide) mimic incretin โ€” increase insulin, decrease glucagon, slow gastric emptying (weight loss). SGLT2 inhibitors (empagliflozin) block renal glucose reabsorption, causing glycosuria (weight loss, cardiorenal benefit, risk of euglycaemic ketoacidosis).

  35. Describe the synthesis and action of thyroid hormones and the role of the hypothalamic-pituitary axis.

    TRH from the hypothalamus stimulates TSH from the anterior pituitary, which drives the thyroid to trap iodide, incorporate it into thyroglobulin tyrosines, and form T4 (thyroxine) and T3. T4 is converted peripherally to the more active T3, which acts on nuclear receptors to increase basal metabolic rate. T3/T4 exert negative feedback on TSH and TRH.

  36. How do carbimazole (methimazole) and propylthiouracil treat hyperthyroidism, and what serious adverse effect must patients be warned about?

    Both inhibit thyroid peroxidase, blocking iodination and coupling of tyrosines (reducing T3/T4 synthesis); propylthiouracil additionally inhibits peripheral T4-to-T3 conversion. The serious adverse effect is agranulocytosis โ€” patients must report sore throat, fever or infection for an urgent full blood count. Propylthiouracil also carries a risk of hepatotoxicity.

  37. How is thyroid hormone replacement (levothyroxine) monitored and dosed?

    Levothyroxine (synthetic T4) is given orally once daily; dose is titrated against serum TSH (aiming to normalise it), checked ~6โ€“8 weeks after any dose change because of the long half-life (~7 days). Over-replacement risks atrial fibrillation and osteoporosis; it should be taken on an empty stomach as calcium/iron impair absorption.

Same Pharmacology syllabus in other exams

The Pharmacology outline above is identical in this exam:

MRCS Part A Pharmacology FAQ

What is in the MRCS Part A Pharmacology syllabus?

MRCS Part A Pharmacology is split into 8 chapters: General Pharmacology, Autonomic Nervous System Pharmacology, Cardiovascular Pharmacology, Central Nervous System Pharmacology, Endocrine Pharmacology, Chemotherapy, Respiratory Pharmacology and Gastrointestinal Pharmacology. Together they contain 30 topics and 97 sub-topics.

How many chapters are in MRCS Part A Pharmacology?

8 chapters, containing 30 topics and 97 sub-topics. The largest chapter is General Pharmacology, with 5 topics.

Are there flashcards for MRCS Part A Pharmacology?

Yes โ€” a 57-card Pharmacology deck, printed in full in the flashcards section of this page and available in the Examius app with spaced repetition. The free plan covers one exam of your choice, including its flashcards; Examius Pro, a one-time purchase, unlocks every other exam and deck.